Total neoadjuvant therapy vs surgery for rectal cancer
Part of Cancer, Digestive system, Injuries & trauma clinical trials.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rectal adenocarcinoma (a type of rectal cancer) confirmed by a biopsy.
- Your tumor is within 10 cm (about 4 inches) of your anus for part one, or up to 12 cm for part two.
- Your cancer has not spread to other organs (stage M0) and has certain features seen on MRI (MRF-, EMVI-).
- You have not had prior chemotherapy or radiation for this rectal cancer (for part one).
- You are in generally good health (ECOG score 0 to 2) and have normal bone marrow, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
This study compares two standard treatment approaches for early-stage rectal cancer that has not spread. One group gets chemo and radiation before surgery, while the other gets chemo, radiation, and more chemo before surgery. The goal is to see which plan is more effective and has fewer side effects.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.